On This Day, Dec. 18: House impeaches President Trump

A chronology of notable events for Dec. 18 highlights constitutional, political and economic milestones: the 13th Amendment abolishing slavery (1865), the 1912 Pujo Committee probe revealing control of over $23.5 billion by J.P. Morgan & 17 firms, and the 2019 U.S. House impeachment of President Donald Trump. Other items with potential economic relevance include General Motors’ 1991 plan to close 21 plants and cut 74,000 jobs and the FDA emergency authorization for Moderna’s COVID-19 vaccine in 2020; the piece is a factual historical roundup rather than market-moving news.

Analysis

Market structure: winners are mRNA-platform plays (MRNA) that captured rapid vaccine authorization and recurring booster revenues; losers are legacy OEMs (GM) exposed to labor/plant rationalization and margin pressure from EV transition. Expect pricing power to shift toward software/biotech pricing (high gross margins) versus capital-intensive autos (low single-digit margins), pressuring auto suppliers and industrial commodity demand by mid-single digits over 12–36 months. Cross-asset: continued biotech upside supports growth equities and high-yield credit in health care, while auto weakness nudges industrial cyclicals and commodity-linked FX (CAD, AUD) lower; option vols for GM should stay elevated near event risk, MRNA vols compress after regulatory clarity.

Risk assessment: tail risks include regulatory setbacks for mRNA IP or vaccine safety (low-probability, high-impact) and large-scale labor strikes/recalls at GM that could force accelerated plant closures. Immediate (days) risks: earnings or FDA announcements; short-term (weeks–months): booster uptake trends and congressional/tariff moves; long-term (quarters–years): structural EV adoption >30% market share which would materially re-rate GM. Hidden dependencies: MRNA revenues depend on booster pricing and gov’t procurement (if procurement drops >30% yoy, revenue shock), GM depends on battery supply and semiconductor cadence.

Trade implications: direct play — establish 2–3% long position in MRNA and hedge with a 6‑month 30% OTM call spread to cap cost, target +30–50% upside within 6–12 months if approvals/booster rollouts continue. For GM, initiate a 1–2% tactical short via 6‑month 20% OTM put spreads (limit drawdown) or buy 6–12 month puts if auto sales miss by >10% q/q; pair trade long MRNA / short GM sized 1:1. Rotate 2–4% portfolio weight from autos/industrial cyclicals into biotech and green energy over next 3 months.

Contrarian angles: consensus may underappreciate mRNA revenue cyclicality — if quarterly vaccine bookings fall >15% vs. street, downside could be rapid; consider trimming MRNA positions on a +30% rally. Conversely, GM’s multiple may over-penalize legacy assets — consider a 12–18 month recovery call spread if GM drops >25% on sentiment alone. Historical parallel: 1990s GM restructurings show deep drawdowns can reverse over multi-year cycles; monitor policy (EV subsidies) and procurement contracts as the primary reversal catalysts.

Key Decisions for Investors

• Establish a 2–3% NAV long position in MRNA within 2 weeks, hedge cost by buying a 6‑month 30% OTM call spread sized to cap premium; target +30–50% upside within 6–12 months tied to additional approvals/booster contracts.
• Initiate a 1–2% tactical short on GM via a 6‑month 20% OTM put spread (limited risk) if U.S. sales or margin guidance misses by >5% q/q; add size only if downside >15% from current levels.
• Implement a pair trade: equal-dollar long MRNA / short GM (1:1) sized 1–2% NAV to capture secular mRNA tailwinds vs. legacy auto headwinds; rebalance monthly and trim long leg if MRNA rallies >30%.
• Rotate 2–4% of portfolio from industrial cyclicals/legacy auto ETFs into biotech (include MRNA) and battery/clean-energy names over next 3 months; accelerate if auto sales data fall >7% m/m or if booster procurement declines >20% yoy.